Avatrombopag (Doptelet) Tablets | Low Platelet Count Treatment

Avatrombopag (Avapag)  is an oral thrombopoietin receptor agonist used to increase platelet counts in adults with chronic immune thrombocytopenia and chronic liver disease-associated thrombocytopenia.

Product Information

Information Details
Generic Name Avatrombopag
Brand Name Doptelet
Drug Class Thrombopoietin Receptor Agonist
Dosage Form Oral Tablet
Indication Low Platelet Count Treatment
Prescription Required
Generic Brand name Avapag

Avatrombopag (Doptelet)

Overview

Avatrombopag, marketed under the brand name Doptelet, is an oral thrombopoietin receptor agonist used to increase platelet counts in adults with thrombocytopenia. It is indicated for patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments and for patients with chronic liver disease who are scheduled to undergo medical or dental procedures.

Low platelet counts can increase the risk of bleeding and bruising. Avatrombopag helps stimulate platelet production, reducing bleeding risk and minimizing the need for platelet transfusions in eligible patients.

How Avatrombopag Works

Avatrombopag acts by stimulating thrombopoietin (TPO) receptors found on bone marrow cells. Activation of these receptors promotes the growth and maturation of megakaryocytes, which are responsible for producing platelets.

As platelet production increases, blood clotting function may improve, helping reduce bleeding complications associated with thrombocytopenia.

Therapeutic Uses

  • Chronic Immune Thrombocytopenia (ITP)
  • Thrombocytopenia associated with Chronic Liver Disease
  • Platelet count improvement before scheduled medical procedures
  • Reduction in the need for platelet transfusions

Benefits of Avatrombopag

  • Oral tablet administration
  • Increases platelet production naturally
  • Helps reduce bleeding risk
  • May decrease the need for platelet transfusions
  • Effective in chronic ITP patients
  • Convenient dosing schedule
  • Suitable for long-term management in selected patients

Dosage and Administration

The dosage of Avatrombopag varies depending on the medical condition, platelet count, and treatment response.

Chronic Liver Disease

Treatment is generally initiated several days before a scheduled procedure to increase platelet counts and reduce bleeding risk.

Chronic Immune Thrombocytopenia

The dose is adjusted according to platelet count response. Regular monitoring is required to maintain platelet levels within the target range.

Patients should take Avatrombopag exactly as prescribed by their healthcare provider. Tablets should be swallowed whole and may be taken with food.

Common Side Effects

Some patients may experience:

  • Headache
  • Fatigue
  • Nausea
  • Fever
  • Abdominal pain
  • Joint pain
  • Dizziness
  • Upper respiratory tract infection

Most side effects are mild to moderate. Patients should seek medical attention if serious adverse effects occur.

Serious Adverse Effects

Although uncommon, serious complications may include:

  • Blood clots (thromboembolic events)
  • Excessively high platelet counts
  • Severe allergic reactions
  • Liver function abnormalities

Regular medical monitoring is recommended during treatment.

Precautions and Warnings

  • Monitor platelet counts regularly during therapy.
  • Use cautiously in patients with a history of thrombosis.
  • Inform healthcare providers about all medications being used.
  • Patients with liver disease should be closely monitored.
  • Use during pregnancy only if the potential benefit outweighs the risk.
  • Breastfeeding mothers should consult their physician before use.

Drug Interactions

Certain medications may affect the effectiveness of Avatrombopag or increase the risk of side effects. Patients should inform their healthcare provider about:

  • Prescription medicines
  • Over-the-counter medications
  • Herbal supplements
  • Vitamins and nutritional products

Storage Conditions

  • Store below 30°C.
  • Keep in the original packaging.
  • Protect from excessive moisture and heat.
  • Keep out of reach of children.

Frequently Asked Questions

What is Avatrombopag used for?

Avatrombopag is used to increase platelet counts in adults with chronic immune thrombocytopenia and chronic liver disease-associated thrombocytopenia.

Is Avatrombopag the same as Doptelet?

Yes. Avatrombopag is the generic name, while Doptelet is the brand name.

Is Avatrombopag a chemotherapy medicine?

No. Avatrombopag is a thrombopoietin receptor agonist and is not a chemotherapy drug.

Can Avatrombopag reduce the need for platelet transfusions?

Yes. In some patients, it may reduce or eliminate the need for platelet transfusions before medical procedures.

Does Avatrombopag require a prescription?

Yes. It should only be used under the supervision of a qualified healthcare professional.

 

Disclaimer

This information is intended for educational purposes only and should not replace professional medical advice. Always consult a qualified healthcare provider regarding diagnosis, treatment, and medication use.

Categories:
  • Low Platelet Count Treatment
  • Thrombocytopenia Treatment
  • Chronic Immune Thrombocytopenia
  • ITP Treatment
  • Chronic Liver Disease Treatment
  • Platelet Count Increase
  • Platelet Disorder Treatment
  • Blood Platelet Medication
  • Bleeding Disorder Treatment
  • Thrombopoietin Receptor Agonist
Let's chat